Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

BACKGROUND: The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Pulm Med
Main Authors: Tweed, Conor D., Crook, Angela M., Dawson, Rodney, Diacon, Andreas H., McHugh, Timothy D., Mendel, Carl M., Meredith, Sarah K., Mohapi, Lerato, Murphy, Michael E., Nunn, Andrew J., Phillips, Patrick P. J., Singh, Kasha P., Spigelman, Melvin, Gillespie, Stephen H.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694514/
https://ncbi.nlm.nih.gov/pubmed/31412895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-019-0907-6
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki